
Tvardi Therapeutics: Pioneering breakthrough medicines for cancers and chronic diseases since 2017.
Tvardi Therapeutics is a clinical-stage biotechnology company founded in 2017 and based in Houston, Texas. The company is dedicated to developing breakthrough medicines targeting diverse cancers, chronic inflammatory diseases, and fibrotic diseases. Tvardi's innovative approach focuses on creating a new class of therapies, including their novel STAT3 inhibitor, TTI-101, which is currently undergoing clinical trials.
Tvardi Therapeutics has made significant strides in the biotech industry, including presenting their Phase 1 clinical trial results for liver cancer at the ASCO Gastrointestinal Cancers Symposium. The company has attracted notable leadership, with Sujal Shah appointed as Chairman and Shaheen Wirk joining the Board of Directors. Tvardi continues to participate in prominent industry conferences, such as the Cowen 44th Annual Health Care Conference, showcasing their commitment to advancing medical research and treatment options.

Tavros Therapeutics

Starton Therapeutics

Treadwell Therapeutics
treadwelltx.com

Therini Bio
therinibio.com

Tavotek Biotherapeutics
tavotek.com

Tigris Pharmaceuticals
tigrispharma.com

Stellanova Therapeutics
stellanovatx.com

Star Therapeutics

Flare Therapeutics
flaretx.com

Tachyon Therapeutics
tachyontx.com

TG Therapeutics
tgtherapeutics.com

Tactiva Therapeutics

Iterion Therapeutics

Blade Therapeutics

Torl Biotherapeutics
torlbio.com
Companies similar to Tvardi Therapeutics include Tavros Therapeutics, Starton Therapeutics, Treadwell Therapeutics and Therini Bio.
Tvardi Therapeutics was founded in 2017.
Tvardi Therapeutics' headquarters is located in Houston, TX, US.
Tvardi Therapeutics' most recent funding round was for $72.4M (USD) in June 2021.
As of Jun 15, 2021, Tvardi Therapeutics has raised a total of $81.4M (USD).
Tvardi Therapeutics has 20 employees as of Feb 5, 2024.